Enteralia Bioscience Italia Revenue

Biotechnology Research • Monza, Lombardy, Italy • 11-20 Employees

Enteralia Bioscience Italia revenue & valuation

Annual revenue	$1,283,325
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$4,200,000
Total funding	No funding

Key Contact at Enteralia Bioscience Italia

Antonio Maggi

Chief Executive Officer

Company overview

Headquarters	Monza, Lombardy, Italy
Websites	enteralia.it enteralia-bioscience.com
NAICS	541714
Keywords	Women'S Health, Gastroenterology, Nutritional Supplements, Iron Deficiency, Anemia, Nutritional Deficiencies, Microbioma, Nutritional Disorders
Founded	2020
Employees	11-20
Socials

Enteralia Bioscience Italia Email Formats

Enteralia Bioscience Italia uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@enteralia.it), used 87.5% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@enteralia.it	87.5%
{first initial}.{last name}	j.doe@enteralia.it	12.5%

About Enteralia Bioscience Italia

Enteralia Bioscience Italia è una giovane e dinamica azienda italiana, nata dall'attività di @Nemysis Ltd. Ci occupiamo di sviluppare soluzioni terapeutiche innovative per supplire a carenze e disturbi nutrizionali comune, con un focus particolare sulla salvaguardia del microbioma umano. La nostra missione è semplice ma ambiziosa: migliorare la qualità della vita attraverso la scienza. Prodotti principali: - IHAT Ferro Nanoparticolato: IHAT è il primo mimetico naturale della ferritina, progettato per correggere la carenza di ferro e l'anemia senza alterare negativamente il microbioma intestinale. La sua sicurezza ed efficacia sono state confermate dall’EFSA. Attualmente venduto in Italia dai nostri partners commerciali KolinPharma S.r.l e Bruno Farmaceutici S.r.l., sotto i marchi Kipfer e Irondelta. - Endopeptidasi E40: Questa innovativa endopeptidasi è resistente alla gastrina, tripsina e chimotripsina. È stata dimostrata la sua capacità di distruggere tutti gli epitopi immuno-stimolatori del glutine, riducendo la risposta infiammatoria esagerata delle cellule T sensibili al glutine. E40 è quindi ideale per la gestione enzimatica dell'intolleranza e della sensibilità al glutine. Attualmente in pipeline di sviluppo.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

Manager

C-Suite

Employees by Department

Enteralia Bioscience Italia has 6 employees across 6 departments.

Departments

Number of employees

Funding Data

Enteralia Bioscience Italia has never raised funding before.

Frequently asked questions

Enteralia Bioscience Italia is located in Monza, Lombardy, IT.

Enteralia Bioscience Italia generates an estimated annual revenue of $1,283,325. This revenue figure reflects the company's market position and business performance in its industry.

Enteralia Bioscience Italia has an estimated valuation of $4,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Enteralia Bioscience Italia was founded in 2020, making it 6 years old. The company has established itself as a significant player in its industry over this time.

Enteralia Bioscience Italia has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Enteralia Bioscience Italia

Antonio Maggi

Chief Executive Officer

4.8

40,000 users